Physician profile
Samer Bolis
NPI 1508247925
$737.28
in general payments reported to CMS, 2019-2025
12 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $15.56 · 2020: $14.92 · 2022: $171 · 2023: $314 · 2024: $222.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $536.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $535.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $256.53 | 2019-2024 | Xarelto |
| Pfizer INC. | $86.01 | 2022-2023 | |
| Novo Nordisk INC | $70.67 | 2022-2024 | Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals Lp | $68.69 | 2023 | Lokelma |
| Novartis Pharmaceuticals Corporation | $62.34 | 2024 | |
| Merck Sharp & Dohme LLC | $61.22 | 2023-2024 | Zerbaxa, Dificid, Recarbrio |
| Ucb, INC. | $35.57 | 2024 | Briviact |
| Fisher & Paykel Healthcare INC | $25.45 | 2024 | Fisher & Paykel Healthcare |
| Gilead Sciences, INC. | $19.62 | 2022 | |
| Vapotherm INC | $18.53 | 2024 | Vapotherm |
| Global Blood Therapeutics, INC. | $17.10 | 2022 | |
| Mylan Specialty L.P. | $15.55 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Samer Bolis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.